CJC-1295 Research
CJC-1295 is a long-acting synthetic GHRH(1-29) analog studied in laboratory and in-vitro models for sustained stimulation of the growth-hormone axis. For research use only.
Also known as: Mod GRF 1-29 / with-DAC · CAS 863288-34-0
CJC-1295 is a 29-amino-acid GHRH analog with substitutions that resist DPP-4 inactivation. The DAC (Drug Affinity Complex) variant binds endogenous albumin covalently, extending circulating half-life. In experimental models it activates pituitary GHRH receptors via Gs/cAMP/PKA, raising GH and IGF-1.
Mechanism of Action
CJC-1295 derives from the bioactive 1-29 fragment of GHRH and carries amino-acid substitutions that protect it from dipeptidyl-peptidase-4 cleavage. In the DAC form, a maleimidoproprionic-acid linker enables covalent binding to circulating albumin after introduction in experimental models, shielding the peptide from renal filtration and proteolysis and extending its measured half-life to several days. Mechanistically it acts like native GHRH: binding the Gs-coupled GHRH receptor on pituitary somatotrophs, elevating cAMP and PKA activity, and promoting pulsatile GH release with secondary IGF-1 elevation. Researchers use it as a long-duration GHRH-axis agonist to study prolonged GH/IGF-1 kinetics without repeated dosing in experimental systems.
Research Applications
In research literature, CJC-1295 is studied for its ability to produce sustained, multi-day elevations in GH and IGF-1 in experimental models, making it a useful tool for examining the duration and amplitude of GH-axis stimulation. Reported research contexts include normalization of growth parameters in GHRH-deficient experimental models, characterization of dose-dependent GH and IGF-1 area-under-curve responses, and comparison of DAC versus non-DAC pharmacokinetic profiles. It is also used alongside ghrelin-receptor agonists in mechanistic studies of synergistic GH release. These applications are limited to laboratory and experimental research.
Synergy & Stacks (research context)
In experimental designs, GHRH analogs such as CJC-1295 are frequently studied alongside selective GHS-R (ghrelin-receptor) agonists like ipamorelin to examine complementary signaling: the GHRH pathway and the ghrelin pathway converge on somatotroph GH release through distinct receptors, and combined activation has been reported to amplify GH output in experimental and in-vitro models beyond either agonist alone. Such co-administration studies are used to probe receptor cross-talk, pulse amplitude, and feedback dynamics. This synergy framing is provided only as research context describing published laboratory observations; it is not a dosing protocol and implies nothing about human use.
Applications at a glance
- Laboratory study of long-duration GH/IGF-1 stimulation
- Pharmacokinetic comparison of DAC vs non-DAC GHRH analogs
- Growth-normalization research in GHRH-deficient experimental models
- Mechanistic co-agonism studies with ghrelin-receptor peptides